Clofarabine vs fludarabine for AML before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study compares two chemotherapy medicines—clofarabine and fludarabine—given at a reduced intensity before an allogeneic stem cell transplant. It aims to see which regimen works better and is safer for people with AML who are eligible for this transplant approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have AML (new or secondary) that is in complete remission for transplant (marrow blast count under 5%) or MDS/LAM with marrow blast count 5% or less
- Your doctor says you can receive a reduced-intensity conditioning regimen (often based on age 60+ or medical conditions if under 60)
- You have a matched donor, and the stem cell graft will be only from peripheral blood (not cord blood)
- You are fit enough for study visits (ECOG 0 to 2) and can use effective contraception if required
- You meet key organ and infection requirements (kidney, liver, heart, and lung tests) and do not have certain excluded conditions (like promyelocytic leukemia or HIV)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
This trial tests a stronger chemotherapy regimen before a stem cell transplant to see if it can reduce the chance of leukemia coming back. It is for adults with acute myeloid leukemia who are in first remission.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
This Phase 3 trial studies the best “conditioning” chemotherapy plan before an allogeneic stem cell transplant for children with AML. It may help improve outcomes by testing an approach for kids who are ready for transplant after relapse or specific high-risk features.
Hear when a new Acute Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.